We are live on ! Find out more
BIO icon

Bio-Rad Laboratories Class A

354 hedge funds and large institutions have $6.43B invested in Bio-Rad Laboratories Class A in 2019 Q3 according to their latest regulatory filings, with 54 funds opening new positions, 148 increasing their positions, 97 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

86% more first-time investments, than exits

New positions opened: 54 | Existing positions closed: 29

53% more repeat investments, than reductions

Existing positions increased: 148 | Existing positions reduced: 97

10% more capital invested

Capital invested by funds: $5.87B → $6.43B (+$562M)

7% more funds holding

Funds holding: 330354 (+24)

2.26% more ownership

Funds ownership: 75.91%78.17% (+2.3%)

36% less funds holding in top 10

Funds holding in top 10: 117 (-4)

69% less call options, than puts

Call options by funds: $9.75M | Put options by funds: $31.4M

Holders
354
Holders Change
+24
Holders Change %
+7.27%
% of All Funds
7.76%
Holding in Top 10
7
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-36.36%
% of All Funds
0.15%
New
54
Increased
148
Reduced
97
Closed
29
Calls
$9.75M
Puts
$31.4M
Net Calls
-$21.7M
Net Calls Change
-$37.2M
Name Holding Trade Value Shares
Change
Change in
Stake
TC
276
TradeLink Capital
Illinois
$266K +$261K +800 New
CCM
277
Coldstream Capital Management
Washington
$265K
Commonwealth Equity Services
278
Commonwealth Equity Services
Massachusetts
$258K +$253K +776 New
TRCT
279
Tower Research Capital (TRC)
New York
$257K +$152K +466 +152%
BIAS
280
Beacon Investment Advisory Services
New Jersey
$251K
ZIM
281
Zacks Investment Management
Illinois
$249K -$1.14M -3,489 -82%
CIBC World Market
282
CIBC World Market
Ontario, Canada
$245K -$191K -584 -44%
Creative Planning
283
Creative Planning
Kansas
$244K +$6.85K +21 +3%
CI
284
Cigna Investments
Connecticut
$242K +$237K +728 New
FCBT
285
First Citizens Bank & Trust
North Carolina
$237K -$332K -1,018 -59%
WAM
286
World Asset Management
Michigan
$231K +$10.1K +31 +5%
BCM
287
BTR Capital Management
California
$230K
LIA
288
LS Investment Advisors
Michigan
$230K +$14.7K +45 +7%
SI
289
Stephens Inc
Arkansas
$218K +$213K +654 New
VCA
290
Verdence Capital Advisors
Maryland
$210K +$206K +631 New
Mackenzie Financial
291
Mackenzie Financial
Ontario, Canada
$205K +$201K +617 New
QI
292
QS Investors
New York
$200K
MAM
293
Meeder Asset Management
Ohio
$197K +$147K +450 +321%
CIA
294
CSat Investment Advisory
Michigan
$170K +$29K +89 +21%
BCI
295
Brinker Capital Investments
Pennsylvania
$149K
HAG
296
HighPoint Advisor Group
Illinois
$144K +$4.89K +15 +4%
SNT
297
Security National Trust
West Virginia
$133K
PCG
298
Private Capital Group
Connecticut
$130K +$121K +370 +1,682%
BFEC
299
Benjamin F. Edwards & Company
Missouri
$126K +$124K +380 New
FL
300
Fort LP
Maryland
$120K +$118K +362 New

BIO Hedge Fund Activity: Q3 2019 in Review

354 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Bio-Rad Laboratories Class A (BIO) for Q3 2019, worth a combined $6.43B — up 9.6% from $5.87B a quarter earlier.

Buyers outnumbered sellers: 54 funds opened new BIO positions and 29 closed out — a net gain of 25 holders — while 148 added to existing stakes and 97 trimmed.

The largest buyer was Acadian Asset Management, opening a new position worth an estimated $121M. The largest seller was Easterly Investment Partners, cutting an estimated $120M.

  • 354 institutional investors held Bio-Rad Laboratories Class A (BIO) as of Q3 2019, up from 330 in Q2 2019.
  • Funds reported $6.43B of Bio-Rad Laboratories Class A stock for Q3 2019, up 9.6% quarter-over-quarter.
  • 54 funds opened new Bio-Rad Laboratories Class A positions in Q3 2019 and 29 closed out, a net change of +25 holders.
  • The largest Bio-Rad Laboratories Class A buyer in Q3 2019 was Acadian Asset Management, an estimated $121M added.
  • The largest Bio-Rad Laboratories Class A seller in Q3 2019 was Easterly Investment Partners, an estimated $120M sold.

Based on aggregated 13F filings for Q3 2019.